Urinary levels of Bcl-2 are elevated in ovarian cancer patients

Gynecologic Oncology

Volumn 112, Issue 1, 2009, Pages 60-67

  Anderson, Nicole S ^a   Bermudez, Yira ^a   Badgwell, Donna ^b   Chen, Ren ^c   Nicosia, Santo V ^a,d   Bast Jr , Robert C ^b   Kruk, Patricia A ^a,d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Bcl 2; Biomarker; Ovarian cancer; Urine

Indexed keywords

CA 125 ANTIGEN; CREATININE; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER GRADING; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GYNECOLOGIC DISEASE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN URINE LEVEL; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 57649096288     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.09.037     Document Type: Article

References (25)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
2. Jacobs I., and Bast Jr. R.C. The CA-125 tumor-associated antigen: a review of the literature. Hum. Reprod. 4 (1989) 1-12
3. Nakase K., Tsuji K., Tamaki S., Tanigawa M., Ikeda T., Miyanishi E., et al. Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies. Cancer Detect. Prev. 29 (2005) 256-259
4. Sauter E.R., Chervoneva I., Diamandis A., Khosrave J.M., Litwin S., and Diamandis E.P. Prostate-specific antigen and insulin-like growth factor binding protein-3 in nipple aspirate fluid are associated with breast cancer. Cancer Detect. Prev. 26 (2002) 149-157
5. Cao Y., Veitonmake N., Keough K., Cheng H., Lee L.S., Cao Y., et al. Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients. Intl. J. Mol. Med. 5 (2000) 547-551
6. Smith S.D., Wheeler M.A., Plescia J., Colberg J.W., Weiss R.M., and Altieri D.C. Urine detection of survivin and diagnosis of bladder cancer. JAMA 285 (2001) 324-328
7. Sutphen R., Xu Y., Wilbanks G.D., Fiorica J., Grendys Jr. E.C., LaPolla J.P., et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol. Biomark. Prev. 13 (2004) 1185-1191
8. Hazelton D., Nicosia R.F., and Nicosia S.V. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin. Cancer Res. 5 (1999) 823-829
9. Woolas R.P., Xu F.J., Jacobs I.J., Yu Y.H., Daly L., Berchuk A., et al. Elevation of multiple serum markers in patients with stage 1 ovarian cancer. J. Natl. Cancer Inst. 85 (1993) 1748-1751
10. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V., Steinberg S.M., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (2002) 572-577
11. Badgwell D., Lu Z., Cole L., Fritsche H., Atkinson E.N., Somers E., et al. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol. Oncol. 106 (2007) 490-497
12. Sagarra R.A., Andrade L.A., Martinez E.Z., Pinto G.A., Syrjanen K.J., and Derchain S.F. P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer. Intl. J. Gynecol. Cancer 12 (2002) 720-727
13. Lowe S.W., and Lin A.W. Apoptosis in cancer. Carcinogenesis 21 (2000) 485-495
14. Walczak H., and Krammer P.H. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp. Cell Res. 256 (2000) 58-66
15. Loeffler M., and Kroemer G. The mitochondrion in cell death control: certainties and incognita. Exp. Cell Res. 256 (2000) 19-26
16. Nagata S. Apoptotic DNA fragmentation. Exp. Cell Res. 256 (2000) 12-18
17. Farrow S.N., and Brown R. New members of the bcl-2 family and their protein partners. Curr. Opin. Gen. Dev. 6 (1996) 45-49
18. Thomenius M.J., and Distelhorst C.W. Bcl-2 on the endoplasmic reticulum: protecting the mitochondria from a distance. J. Cell. Sci. 116 (2003) 4493-4499
19. Khalifeh I., Munkarah A., Lonarado F., Malone J.M., Morris R., and Lawrence W.D. Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma. Int. J. Gynecol. Pathol. 23 (2004) 162-169
20. Ackermann E.J., Taylor J.K., and Bennett C.F. The role of antiapoptotic Bcl-2 family members in endothelial apoptosis elucidated with antisense oligonucleotides. J. Biol. Chem. 274 (1999) 11245-11252
21. Lickliter J.D., Wood N.J., Johnson L., McHugh G., Tan J., Wood F., et al. HA14-1 selectively induces apoptosis in Bcl-2 overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death. Leukemia 17 (2003) 2074-2080
22. Nor J.E., Christensen J., Liu J., Peters M., Mooney D.J., Strieter R.M., and Polverini P.J. Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res. 61 (2001) 2183-2188
23. Ievolino A., Trisciuoglio D., Bibatti D., Candiloro A., Biroccio A., Zupi G., and Del Bufalo D. Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J. 16 (2002) 1453-1455
24. Friedrich M.G., Weisenberger D.J., Cheng J.C., Chandrasoma S., Siegmund K.D., Gonzalgo M.L., et al. Detection of methylated apoptosis-related genes in urine sediments of bladder cancer patients. Clin. Cancer Res. 10 (2004) 7457-7465
25. Yu J., Wang Z., Zhang H., Qian Z., Xu H., Gao B., et al. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin. Cancer Res. 13 (2007) 7296-7304